Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.
Employees: 51-200
Founded date: 2018
Investors 3
| Date | Name | Website |
| - | Altium Cap... | altiumcap.... |
| - | Spur Capit... | spurcapita... |
| - | Roivant | roivant.co... |
Mentions in press and media 15
| Date | Title | Description |
| 14.12.2025 | Disney Invests in OpenAI, Tech Stocks Wobble Amid AI Concerns | Disney announced a $1 billion investment in OpenAI, granting access to its characters for AI-generated content. This move coincides with a market shift as investors reassess the AI boom, triggered by Oracle’s disappointing earnings. While t... |
| 10.12.2025 | S&P 500, Dow close at record highs as Oracle sparks rush out of AI trade into broader market | The Dow Jones Industrial Average and S&P 500 reached new heights on Thursday, as a Federal Reserve interest rate cut followed by disappointing Oracle results prompted investors to move out of high-flying tech stocks and into names that ... |
| 18.07.2025 | Improving Clinical Tech Adoption: Site-Centric Approaches, Upcoming Webinar Hosted by Xtalks | www.advarra.com In this free webinar, gain insights to identify and address the key barriers that prevent sites from adopting sponsor-deployed study technologies. Attendees will learn about proven strategies to evaluate, implement and suppo... |
| 13.11.2024 | Prevent Blindness Declares Fifth Annual Thyroid Eye Disease Awareness Week as Nov. 18-24, 2024 | Prevent Blindness offers free educational materials for patients and healthcare professionals for its 5th Annual Thyroid Eye Disease Awareness Week. Prevent Blindness provides free educational materials on Thyroid Eye Disease, including a n... |
| 01.11.2024 | HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update | HanAll records revenue of 36.8 billion KRW in the third quarter, with an operating profit of 430 million KRW. Results for the Phase 1 study in healthy subjects for HL192 (ATH-399A), a novel compound targeting Parkinson's Disease, are expect... |
| 28.07.2024 | HanAll Biopharma: Navigating Challenges and Opportunities in Q2 2024 | HanAll Biopharma, a global player in the biopharmaceutical arena, recently unveiled its financial results for the second quarter of 2024. The numbers tell a story of resilience amid challenges. Total revenue reached 31.6 billion KRW, a slig... |
| 26.07.2024 | HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update | HanAll reports strong financial performance with second quarter total revenue of 31.6 billion KRW, driven by the strong sales from the key products. HanAll expands collaboration with Turn Biotechnologies through an exclusive licensing agree... |
| 26.07.2024 | HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update | HanAll reports strong financial performance with second quarter total revenue of 31.6 billion KRW, driven by the strong sales from the key products. HanAll expands collaboration with Turn Biotechnologies through an exclusive licensing agree... |
| 30.04.2024 | HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update | Delivered solid performance to start 2024, with record-breaking first quarter revenue of 34.1 billion KRW. Strong sales momentum continued from key products, funding investments in ongoing R&D programs. Phase 3 VELOS-4 study of tanfaner... |
| 21.03.2024 | HanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update | Full-year 2023 net revenue reaches 135 billion KRW, driven by strong sales growth. R&D momentum persisted with promising developments in anti-FcRn antibodies HL161ANS and batoclimab, positioning them as potentially best-in-class treatme... |
Show more